Molecular structure of THZ1, CAS Number: 1604810-83-4
THZ1 (CAS 1604810-83-4)
Alternate Names:
N-[3-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-4-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]-benzamide
CAS Number:
1604810-83-4
Molecular Weight:
566.1
Molecular Formula:
C31H28ClN7O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
THZ1 (CAS 1604810-83-4) References
- THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing. | Nilson, KA., et al. 2015. Mol Cell. 59: 576-87. PMID: 26257281
- Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation. | Ma, X., et al. 2018. J Cancer. 9: 3149-3155. PMID: 30210638
- THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism. | Cheng, ZJ., et al. 2019. Acta Pharmacol Sin. 40: 814-822. PMID: 30446732
- CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263. | Huang, T., et al. 2019. Cell Death Dis. 10: 602. PMID: 31399555
- THZ1, a covalent CDK7 inhibitor, enhances gemcitabine-induced cytotoxicity via suppression of Bcl-2 in urothelial carcinoma. | Kuo, KL., et al. 2021. Am J Cancer Res. 11: 171-180. PMID: 33520367
- CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway. | Chow, PM., et al. 2021. Cancer Lett. 507: 70-79. PMID: 33741425
- CDK7 Inhibitor THZ1 Induces the Cell Apoptosis of B-Cell Acute Lymphocytic Leukemia by Perturbing Cellular Metabolism. | Abudureheman, T., et al. 2021. Front Oncol. 11: 663360. PMID: 33889549
- Elevation of effective p53 expression sensitizes wild-type p53 breast cancer cells to CDK7 inhibitor THZ1. | Wang, Y., et al. 2022. Cell Commun Signal. 20: 96. PMID: 36058938
- THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours. | Sun, J., et al. 2022. Cell Commun Signal. 20: 138. PMID: 36076237
- The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study. | Huang, L., et al. 2023. Clin Transl Med. 13: e1500. PMID: 38037549
Inhibitor of:
AFF4, ATXN1L, BC024659, Cdk7, Cdk8, CNOT8, CPSF3L, cyclin H, E47, EG624855, ELL2, hnRNP L, IκB-β, INTS10, INTS8, INTS9, Kin28, L-Myc, Med2p, MEDA-4, N-Myc, NELF, Obox1, p107, Pcf11, PHR1, POLR2E, POLR2I, POLR2J2, PRRT4, Rad21, RNA pol σ H, Rpb3, RPRD1B, SC35, SFRS12, Sororin (CDCA5), Sox-8, TAF I p63_TAF I p68, TAFII-18, TFIIH p89, TRAP230, and ZNF606.Activator of:
C87499, C87977, Cig2, NELF-B, and SSU72.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
THZ1, 1 mg | sc-507542 | 1 mg | $95.00 |